Fuyuki F Inagaki
Overview
Explore the profile of Fuyuki F Inagaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inagaki N, Oki Y, Ikeda S, Tulakarnwong S, Shinohara M, Inagaki F, et al.
Biomater Sci
. 2024 Jul;
12(17):4354-4362.
PMID: 38967234
Pancreatic islet transplantation is an effective treatment for type I diabetes mellitus. However, many problems associated with pancreatic islet engraftment remain unresolved. In this study, we developed a hydrogel microwell...
2.
Inagaki F, Kano M, Furusawa A, Kato T, Okada R, Fukushima H, et al.
Cancer Sci
. 2024 Apr;
115(7):2396-2409.
PMID: 38671582
Near-infrared photoimmunotherapy (NIR-PIT) is a new type of cancer therapy that employs antibody-IRDye700DX conjugates (AbPCs) and near-infrared (NIR) light at a wavelength of 689 nm, the excitation wavelength of IR700....
3.
Inagaki F, Wakiyama H, Furusawa A, Okada R, Kato T, Fujimura D, et al.
Biomed Pharmacother
. 2023 Feb;
160:114390.
PMID: 36791566
The bones are a common site for metastasis arising from solid tumors such as breast and prostate cancer. Chemotherapy, including immunotherapy, is rarely curative. Radiotherapy with pain palliation can temporize...
4.
Inagaki F, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297471
Disialoganglioside (GD2) is a subtype of glycolipids that is highly expressed in tumors of neuroectodermal origins, such as neuroblastoma and osteosarcoma. Its limited expression in normal tissues makes GD2 a...
5.
Sugita A, Inagaki F, Takemura N, Nakamura M, Ito K, Mihara F, et al.
Surg Case Rep
. 2022 Oct;
8(1):200.
PMID: 36264514
Background: The perioperative mortality rate is high in patients with coronavirus disease 2019 (COVID-19), and infection control measures for medical care providers must be considered. Therefore, the timing for surgery...
6.
Inagaki F, Takemura N, Ito K, Mihara F, Kurokawa T, Kokudo N
Glob Health Med
. 2022 Jan;
3(6):406-408.
PMID: 35036623
Indocyanine green (ICG) is a fluorescent dye that selectively accumulates in primary hepatocellular carcinoma (HCC) as well as in extrahepatic metastases of HCC. Reported here is a case of metachronous...
7.
Inagaki F, Fujimura D, Furusawa A, Okada R, Wakiyama H, Kato T, et al.
Cancer Sci
. 2021 Feb;
112(3):1326-1330.
PMID: 33543819
Near-infrared photoimmunotherapy (NIR-PIT) is a new type of cancer treatment, which was recently approved in Japan for patients with inoperable head and neck cancer. NIR-PIT utilizes antibody-IRDye700DX (IR700) conjugates and...
8.
Inagaki F, Fujimura D, Furusawa A, Okada R, Wakiyama H, Kato T, et al.
Mol Pharm
. 2021 Jan;
18(3):1238-1246.
PMID: 33502869
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that uses antibody-IRDye700DX (IR700) conjugates and was recently approved in Japan for patients with inoperable head and neck cancer. Exposure of...
9.
Inagaki F, Fujimura D, Ansteatt S, Okada R, Furusawa A, Choyke P, et al.
ACS Omega
. 2020 Jul;
5(25):15657-15665.
PMID: 32637840
Targeted near-infrared (NIR) fluorescence probes are playing a significant role in biomedical imaging because NIR penetrates deeper into tissues and is associated with reduced autofluorescence compared to visible light fluorescence...
10.
Inagaki N, Inagaki F, Kokudo N, Miyajima A
FEBS Lett
. 2019 Jan;
593(4):386-394.
PMID: 30609020
Mesothelial cells, which cover the surface of visceral organs and serous cavities in mammals, play a crucial role in preventing adhesion. We previously reported that primary mesothelial progenitor cells (MPCs)...